Request an invite

Mylotarg: how long were the pivotal tox studies?

gemtuzumab ozogamicin · CD33
Longest pivotal study
12 weeks
“A GLP-compliant general toxicity study in monkeys was also completed in which 12 doses of gemtuzumab ozogamicin were given once weekly by intravenous bolus injection to groups of 3 male and 3 female cynomolgus monkeys at doses of 0 (sterile water), 2.2, 6.6, or 11 mg/m2 /week.”
✓ VerifiedEMA assessment report, p. 35Source ↗
Pivotal GLP studies
6-week (weekly IV) rat and monkey with 4-week recovery; 6-cycle monkey cell-line bridging study; 12-week weekly IV monkey
“Rats were administered 6 weekly doses at 0 (PBS control), 7.2 (hP67.6 antibody control), or CL 555,201 (GO) at doses of 0.6, 2.4, or 7.2 mg/m2 /week and observed for an additional 4 weeks.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Route in tox
IV (weekly bolus/infusion)
“Monkeys were administered 6 weekly IV doses at 0 (PBS control), 22 (hP67.6 antibody control), or CL 555,201 at doses of 2.4, 7.2, or 22 mg/m2 /week (5, 15 or 45 mcg/kg/week calicheamicin equivalents) and observed for an additional 4 weeks.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗

Same question, other ADCs

Adcetris

brentuximab vedotin · CD30
26 weeks

Besponsa

inotuzumab ozogamicin · CD22
26 weeks

Datroway

datopotamab deruxtecan · Trop-2
13 weeks

Decnupaz

pivekimab sunirine · CD123
13 weeks

Elahere

mirvetuximab soravtansine · FRα
10 weeks

Emrelis

telisotuzumab vedotin · c-Met
13 weeks

Enhertu

fam-trastuzumab deruxtecan · HER2
13 weeks

Kadcyla

ado-trastuzumab emtansine · HER2
26 weeks

Padcev

enfortumab vedotin · Nectin-4
13 weeks

Polivy

polatuzumab vedotin · CD79b
10 weeks

Tivdak

tisotumab vedotin · Tissue factor
13 weeks

Trodelvy

sacituzumab govitecan · Trop-2
13 weeks

Zynlonta

loncastuximab tesirine · CD19
13 weeks

Summary across all 14 ADCs →